821 related articles for article (PubMed ID: 25437458)
1. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
Escalada FJ
Med Clin (Barc); 2014 Sep; 143 Suppl 2():2-7. PubMed ID: 25437458
[TBL] [Abstract][Full Text] [Related]
2. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
Escalada FJ
Med Clin (Barc); 2014; 143 Suppl 2():2-7. PubMed ID: 25326836
[TBL] [Abstract][Full Text] [Related]
3. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes.
Gautier JF; Choukem SP; Girard J
Diabetes Metab; 2008 Feb; 34 Suppl 2():S65-72. PubMed ID: 18640588
[TBL] [Abstract][Full Text] [Related]
4. The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions.
Girard J
Diabetes Metab; 2008 Dec; 34(6 Pt 1):550-9. PubMed ID: 19036624
[TBL] [Abstract][Full Text] [Related]
5. Incretin hormones: Their role in health and disease.
Nauck MA; Meier JJ
Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
[TBL] [Abstract][Full Text] [Related]
6. Incretins: their physiology and application in the treatment of diabetes mellitus.
Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
[TBL] [Abstract][Full Text] [Related]
7. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Hansotia T; Drucker DJ
Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
[TBL] [Abstract][Full Text] [Related]
8. Incretins and Their Endocrine and Metabolic Functions.
Seufert J
Endocr Dev; 2017; 32():38-48. PubMed ID: 28873383
[TBL] [Abstract][Full Text] [Related]
9. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
10. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
Lam NT; Kieffer TJ
Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
[TBL] [Abstract][Full Text] [Related]
11. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
[TBL] [Abstract][Full Text] [Related]
12. [Incretin and bone].
Yamada Y
Clin Calcium; 2009 Sep; 19(9):1312-7. PubMed ID: 19721203
[TBL] [Abstract][Full Text] [Related]
13. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade.
Aulinger BA; Bedorf A; Kutscherauer G; de Heer J; Holst JJ; Göke B; Schirra J
Diabetes; 2014 Mar; 63(3):1079-92. PubMed ID: 24296715
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 and control of insulin secretion.
Thorens B
Diabete Metab; 1995 Dec; 21(5):311-8. PubMed ID: 8586147
[TBL] [Abstract][Full Text] [Related]
15. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes.
Gautier JF; Fetita S; Sobngwi E; Salaün-Martin C
Diabetes Metab; 2005 Jun; 31(3 Pt 1):233-42. PubMed ID: 16142014
[TBL] [Abstract][Full Text] [Related]
16. [Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
Scheen AJ
Rev Med Liege; 2007 Apr; 62(4):217-21. PubMed ID: 17566392
[TBL] [Abstract][Full Text] [Related]
17. New physiological effects of the incretin hormones GLP-1 and GIP.
Asmar M
Dan Med Bull; 2011 Feb; 58(2):B4248. PubMed ID: 21299928
[TBL] [Abstract][Full Text] [Related]
18. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Deacon CF
Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():23-31. PubMed ID: 17877544
[TBL] [Abstract][Full Text] [Related]
19. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.
Yamagishi S; Matsui T
Curr Pharm Des; 2011 Dec; 17(38):4379-85. PubMed ID: 22204436
[TBL] [Abstract][Full Text] [Related]
20. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]